Jacobson Pharmaceutical (02633.HK) announced its annual performance, with a net profit attributable to equity holders of approximately 301 million Hong Kong dollars, representing a year-on-year increase of 12.69%.

The Zhtng Financial APP reported that Jacobson Pharmaceuticals (02633.HK) announced its annual performance for the year ending March 31, 2025, with a revenue of approximately 1.577 billion Hong Kong dollars from its continuing operations, an increase of about 7.4% year-on-year. The company's net profit attributable to equity holders is approximately 301 million Hong Kong dollars, a growth of 12.69% year-on-year; earnings per share are 15.15 Hong Kong cents, with a proposed final cash dividend of 5.50 Hong Kong cents per share and a special cash dividend of 6.00 Hong Kong cents per share.